Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 31 of 40, showing 5 Applications out of 196 total, starting on record 151, ending on 155

# Protocol No Study Title Investigator(s) & Site(s)

151.

ECCT/17/03/05   HOPE Sickle Cell Disease Clinical Study
    A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease   
Principal Investigator(s)
1. Videlis Nduba
2. Jessie Nyokabi Githanga
Site(s) in Kenya
1. Gertrude\'s Children\'s Hospital (Nairobi City county)
2. Strathmore University Medical Center (Nairobi City county)
3. KEMRI CRDR Clinical Research clinic at Chandaria Health Center (Nairobi City county)
4. KEMRI Kondele Childrens Hospital Center for Clinical Research (Kisumu county)
5. KEMRI Clinical Research Center at Siaya County Referral Hospital (Siaya county)
 
View

152.

ECCT/16/12/02   Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis:
    Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial.   
Principal Investigator(s)
1. ISAAC TSIKHUTSU
Site(s) in Kenya
KEMRI/WRP, KERICHO
 
View

153.

ECCT/16/11/03   COAST
    Childrens Oxygen Administration Strategies Trial   
Principal Investigator(s)
1. Kathryn Maitland
Site(s) in Kenya
1. Kilifi County Hospital (Kilifi county)
2. Coast Provincial General Hospital (Mombasa county)
 
View

154.

ECCT/16/08/01   A5349/TBTC S31
    A5349/TBTC S31 “Rifapentine-containing treatment shortening regimens for pulmonary tuberculosis: A randomized, open-label, controlled phase 3 clinical trial”   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Walter Reed Project (Kericho county)
 
View

155.

ECCT/16/07/02   A Randomized Trial of Inflienza Vaccine to Reduce Adverse Vascular Events
    A Randomized Trial of Inflienza Vaccine to Reduce Adverse Vascular Events   
Principal Investigator(s)
1. Mark Loeb
Site(s) in Kenya
The Aga Khan University Hospital
 
View